Genetic markers predicting sulphonylurea treatment outcomes in type 2 diabetes patients: current evidence and challenges for clinical implementation - PubMed (original) (raw)

Review

doi: 10.1038/tpj.2015.95. Epub 2016 Jan 26.

Affiliations

Review

Genetic markers predicting sulphonylurea treatment outcomes in type 2 diabetes patients: current evidence and challenges for clinical implementation

N K Loganadan et al. Pharmacogenomics J. 2016 Jun.

Abstract

The clinical response to sulphonylurea, an oral antidiabetic agent often used in combination with metformin to control blood glucose in type 2 diabetes (T2DM) patients, has been widely associated with a number of gene polymorphisms, particularly those involved in insulin release. We have reviewed the genetic markers of CYP2C9, ABCC8, KCNJ11, TCF7L2 (transcription factor 7-like 2), IRS-1 (insulin receptor substrate-1), CDKAL1, CDKN2A/2B, KCNQ1 and NOS1AP (nitric oxide synthase 1 adaptor protein) genes that predict treatment outcomes of sulphonylurea therapy. A convincing pattern for poor sulphonylurea response was observed in Caucasian T2DM patients with rs7903146 and rs1801278 polymorphisms of the TCF7L2 and IRS-1 genes, respectively. However, limitations in evaluating the available studies including dissimilarities in study design, definitions of clinical end points, sample sizes and types and doses of sulphonylureas used as well as ethnic variability make the clinical applications challenging. Future studies need to address these limitations to develop personalized sulphonylurea medicine for T2DM management.

PubMed Disclaimer

Similar articles

Cited by

References

    1. N Engl J Med. 2004 Apr 29;350(18):1838-49 - PubMed
    1. J Diabetes Investig. 2013 Sep 13;4(5):445-9 - PubMed
    1. J Clin Endocrinol Metab. 2006 Jun;91(6):2334-9 - PubMed
    1. Cell. 2012 Mar 16;148(6):1160-71 - PubMed
    1. Diabetes Care. 2015 Jan;38(1):140-9 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources